Century Therapeutics Holds 2025 Annual Stockholders Meeting

Century Therapeutics ( (IPSC) ) just unveiled an update.

On June 12, 2025, Century Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, Daphne Quimi and Carlo Rizzuto, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP’s appointment as the company’s independent registered public accounting firm for the 2025 fiscal year was ratified. These decisions reflect the company’s ongoing efforts to strengthen its governance and ensure financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.

Century Therapeutics’ overall score reflects its strong recent financial results and strategic clinical advancements, which are slightly offset by ongoing operational losses and valuation challenges. The technical indicators suggest moderate market interest.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics, Inc. operates in the biotechnology industry, focusing on developing transformative allogeneic cell therapies for cancer treatment.

Average Trading Volume: 738,712

Technical Sentiment Signal: Sell

Current Market Cap: $49.58M

Find detailed analytics on IPSC stock on TipRanks’ Stock Analysis page.